Silver House
Mr Brain Health is dedicated to transforming brain health through innovative approaches, including the BATWatch Protocol, which emphasizes early detection and proactive management of Alzheimer's and other dementias. The company aims to reduce stigma, improve diagnosis accuracy, and empower individuals to take control of their cognitive health using science, technology, and community engagement.
Industries
Nr. of Employees
medium (51-250)
Products
Clinical risk scoring algorithm (BAT Level Index)
Algorithmic score that integrates multi‑test biomarker results, genetic risk factors, and mechanism panel outputs to produce a single risk metric to inform testing recommendations and treatment eligibility.
Autophagy‑focused therapeutic protocol (rapamycin‑based)
Structured treatment framework that defines dosing, timing, and monitoring of autophagy‑promoting therapy to reduce aggregated beta‑amyloid and tau as part of a biomarker‑driven prevention strategy.
Clinical risk scoring algorithm (BAT Level Index)
Algorithmic score that integrates multi‑test biomarker results, genetic risk factors, and mechanism panel outputs to produce a single risk metric to inform testing recommendations and treatment eligibility.
Autophagy‑focused therapeutic protocol (rapamycin‑based)
Structured treatment framework that defines dosing, timing, and monitoring of autophagy‑promoting therapy to reduce aggregated beta‑amyloid and tau as part of a biomarker‑driven prevention strategy.
Services
Blood‑based biomarker testing for beta‑amyloid and tau
Clinical blood tests offered to quantify beta‑amyloid and tau levels for early risk assessment and longitudinal monitoring; ordered via clinician workflow/telehealth and processed through laboratory partners.
Longitudinal biomarker monitoring and management protocol
Ongoing program combining periodic biomarker testing, digital monitoring, and individualized intervention plans to track and manage Alzheimer’s risk over time.
Clinical research participation and data contribution
Automatic enrollment in de‑identified research using clinical and digital data collected during care with the option to opt out; supports observational analyses and third‑party collaborations.
Blood‑based biomarker testing for beta‑amyloid and tau
Clinical blood tests offered to quantify beta‑amyloid and tau levels for early risk assessment and longitudinal monitoring; ordered via clinician workflow/telehealth and processed through laboratory partners.
Longitudinal biomarker monitoring and management protocol
Ongoing program combining periodic biomarker testing, digital monitoring, and individualized intervention plans to track and manage Alzheimer’s risk over time.
Clinical research participation and data contribution
Automatic enrollment in de‑identified research using clinical and digital data collected during care with the option to opt out; supports observational analyses and third‑party collaborations.
Expertise Areas
- Blood‑based biomarker diagnostics for Alzheimer’s risk
- Biomarker‑driven preventive neurology
- Telehealth clinical workflows and coordination
- Clinical decision support and risk‑scoring algorithms
Key Technologies
- Blood‑based beta‑amyloid and tau assays
- Multi‑assay integration / multi‑test methodology
- Clinical decision algorithms (risk index)
- Cloud data lake and evidence matrix